Mangrove Partners Mereo Biopharma Group PLC Transaction History
Mangrove Partners
- $637 Million
- Q1 2025
A detailed history of Mangrove Partners transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Mangrove Partners holds 8,636,485 shares of MREO stock, worth $23.3 Million. This represents 3.05% of its overall portfolio holdings.
Number of Shares
8,636,485
Previous 8,636,485
-0.0%
Holding current value
$23.3 Million
Previous $30.2 Million
35.71%
% of portfolio
3.05%
Previous 4.71%
Shares
4 transactions
Others Institutions Holding MREO
# of Institutions
100Shares Held
112MCall Options Held
1MPut Options Held
668K-
Janus Henderson Group PLC London, X022.7MShares$61.4 Million0.03% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$41.3 Million0.99% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.82MShares$21.1 Million1.11% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$18.1 Million0.38% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD6.68MShares$18 Million0.9% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $337M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...